Concurent Chemoradiotherapy in Head and Neck Cancers
Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
To compare the efficacy and toxicities of the combination between weekly docitaxel and
cisplatin (every3 week) concurrent with radiation versus the standard concurrent
chemoradiotherapy with high dose cisplatin (100mg\m2) for locally advanced HNSCC